HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.
BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Hepatic Arterial Infusion Chemotherapy|Lenvatinib|PD-1|Systemic Therapy
PROCEDURE: hepatic artery infusion chemotherapy|DRUG: Lenvatinib + PD-1 monoclonal antibody
Overall survival, The OS is defined as the time from the initiation of any combination treatment to death due to any cause., Up to approximately 2 years
Progression free survival(PFS) (Overall), The PFS is defined as the time from the initiation of any combination treatment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first., Up to approximately 2 years|Progression free survival(PFS) of intra-hepatic lesions, The PFS is defined as the time from the initiation of any combination treatment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first., Up to approximately 2 years|Progression free survival(PFS) of extra-hepatic lesions, The PFS is defined as the time from the initiation of any combination treatment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first., Up to approximately 2 years|Progression free survival(PFS) of portal vein tumor thrombus (PVTT), The PFS is defined as the time from the initiation of any combination treatment to the first documented progressive disease of PVTT or death due to any cause, whichever occurs first., Up to approximately 2 years|Objective response rate(ORR) per RESCIST 1.1, The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1., Up to approximately 2 years|ORR per mRECIST, The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST., Up to approximately 2 years|ORR of PVTT, The ORR is defined as the proportion of patients with a documented CR or PR of PVTT., Up to approximately 2 years|Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0, The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0., Up to approximately 2 years
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.